What Happened?
Cambridge, MA-based Theseus Pharmaceuticals Appointed Alicja Januszewicz as Senior Vice President of People and Culture
About the Company
Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).
About the Person
Alicja Winiarska Januszewicz is Senior Vice President of People and Culture at Theseus Pharmaceuticals. Previously, Alicja held various senior HR leadership roles in the industry.
Info Source
News
Short Profile